BACKGROUND: Pathogen inactivation and cold or cryopreservation of platelets (PLTs) both significantly affect PLT function. It is not known how PLTs function when both are combined.
C onventional, room temperature (RT) storage of platelets (PLTs) limits shelf life to between 4 and 7 days because of the risk of bacterial contamination and the decrease in PLT function called platelet storage lesion. 1 The limited shelf life of PLT concentrates (PCs) hampers efficient inventory management and puts pressure on blood banks trying to balance risks of shortage with risks of wastage. Prolonging PC shelf life could overcome this problem and has been investigated for decades with a focus on cold storage (1-6 C) 2 and cryopreservation (−80 to −196 C). 3, 4 Cold storage can potentially increase PC shelf life beyond 7 days of storage. 5 Several reports indicate that cold-stored PLTs are functionally "primed" suggesting that these are in a state of heightened responsiveness to hemostatic stimuli. [5] [6] [7] The main obstacle for cold-stored PLTs is the significantly faster clearance from circulation compared to RT storage.
This may be less relevant in acutely bleeding patients who require immediate hemostasis more than extended PLT circulation times. 10 Cryopreservation can increase shelf life of PLTs even longer, to at least 2 years. In this case, PLTs are hyperconcentrated in 5% to 6% dimethyl sulfoxide (DMSO) as cryoprotectant. 11 Cryopreservation has a profound impact on PLT function in vitro with significantly decreased responses to agonists and a substantial increase in storage lesion markers like microparticle (MP) formation, P-selectin, and phosphatidylserine (PS) expression. [12] [13] [14] Despite this decreased responsiveness, cryopreserved PLTs may somehow retain hemostatic function particularly as procoagulants. [14] [15] [16] [17] This is moreover in line with clinical experience of cryopreserved PC use in the military 18 and in a recent trial with bleeding patients with thrombocytopenia. 19 In recent years, pathogen inactivation treatments of PCs have been introduced in several countries to decrease the risk of transfusion-transmitted infections. 20 Three pathogen inactivation treatments have been developed for PLTs and all are based on treatment of PC with ultraviolet (UV) light with or without photosensitizer. The main biochemical principle of all pathogen inactivation methods is prevention of replication by chemical modification of genetic material in pathogens. Because PLTs are anucleate, relevant chemical modification in PLTs is believed to be minimal. 21 However, all three pathogen inactivation methods impact PLT function. [22] [23] [24] For instance, the amotosalen photochemical treatment (AS-PCT) method significantly and irreversibly modifies PLT phospholipids in the PLT membrane. 24 Implementation of pathogen inactivation led to further restriction of PC shelf life from 7 to 5 days in Belgium because hemovigilance data had shed doubt on transfusion efficacy of stored pathogen-inactivated PCs. 21 In surrounding EU countries longer storage times have been licensed. This decision spurred investigation to alternative storage methods of PCs in the context of pathogen inactivation. This study investigated the effect of storage at 4 or −80 C of PCs treated with AS-PCT compared to standard untreated PCs.
MATERIALS AND METHODS
A detailed description of all materials and methods is included in Appendix S1 (available as supporting information in the online version of this paper).
Study design for cold storage
Platelet concentrates (PCs) were prepared by pooling of six buffy coats in 65% (vol/vol) additive solution (SSP+, MacoPharma) derived from whole blood donations. All donors consented in writing to the use of their products for scientific research. This study was approved by the ethical committee of the University Hospital of Antwerp (18/24/289). A pooland-split design was used. Four PCs were pooled then gently mixed and divided into four equal PCs. Two of these were subjected to AS-PCT (Intercept, Cerus Corporation), the other two were left untreated (i.e., standard). Samples were taken at this time point (Day [D]2-21 C) and PCs were immediately stored according to the following conditions. One standard and one AS-PCT PC were stored for an additional 3 days at RT (D5-21 C) with constant agitation (PC900i, Helmer Scientific). The other standard and AS-PCT PCs were stored for an additional 3 days at 4 C without agitation (D5-4 C). Experiments were performed on all D2 and D5 samples (n = 6 biological repeats). Cold-stored PCs were incubated for 10 minutes on the PLT agitator at RT before sampling.
Study design for cryopreservation
A pool-and-split design was used. Two PCs were pooled then gently mixed and redivided into two paired PCs. One was subjected to AS-PCT, and the other was untreated (i.e., standard). Both PCs were conditioned for cryopreservation by methods described elsewhere. 14, 25, 26 In brief, a solution of 27% (vol/vol) DMSO and 0.9% NaCl (wt/vol) in water was added to all PCs yielding a final 6% (vol/vol) DMSO concentration. Next, the PCs were hyperconcentrated by centrifugation, a large volume of supernatant was taken off, and the PLT pellet was resuspended in a minimal volume of remaining supernatant. The entire conditioning regimen was never longer than 2 hours. For the 21 C arm, a small sample was taken from both the standard and the AS-PCT bag followed by addition of ABO/D-matched plasma to yield the original PLT concentration. The cryopreservation arm was stored at −80 C for at least 48 hours. The cryopreservation arm was thawed in a water bath for 8 minutes until reaching 30 C and then resuspended in ABO/D-matched plasma equally prewarmed to 30 C. 26 These PCs were held undisturbed for 30 minutes at RT before sampling and performing experiments. Power analysis requested a larger sample size for the cryopreservation study (n = 8) compared to the cold storage study (n = 6) because the estimated effect sizes of outcomes between standard and AS-PCT conditions were expected to be smaller.
Microfluidic flow chambers with reconstituted blood
Fresh blood was reconstituted with PLTs from the PC aiming for an average of 40% hematocrit and 250 × 10 9
PLTs/L. Sample preparation and fluorescent labeling with 3,3 0 -dihexyloxacarbocyanine iodide (Sigma-Aldrich) and blue fluorescent dye (Alexa Fluor 405, Life Technologies) was as published before. 22, 23, 27 Adhesion of PLTs onto collagen and formation of fibrin was studied by monitoring changes in median fluorescence of respective fluorophores as a function of time during perfusion of the reconstituted and recalcified blood at a wall shear rate of 1000/sec as described previously. 27 PLT adhesion rate (/sec) indicates the rate of PLT deposition. The variables retrieved for fibrin deposition included coagulation rate (/sec), which is the linear portion of fibrin deposition kinetics and coagulation onset (sec). This is the lag time indicating the moment of coagulation onset defined as the intercept with the x-axis of the extrapolated linear regression of the thrombus formation by fibrin fluorescence. This analysis takes into account thrombus growth in the z-plane. The outcome variables were extracted from the raw fluorescence data using a software plugin developed in computer software (MatLab, MathWorks).
Thrombin generation assay
Generation of thrombin in vitro was analyzed with a thrombin generation assay kit (Technoclone GmbH) according to the manufacturer's instructions in a 96-well format. PLTs were resuspended in heterologous human pooled (n = 38) plasma to final concentrations of 10 × 10 converted to thrombin concentrations based on a calibration kit and a mathematical script. 28 Peak thrombin measures the maximal concentration of thrombin formed during the course of the assay, lag time measures the time until a threshold concentration of thrombin is reached, and endogenous thrombin potential (ETP) corresponds to the area under the curve.
Statistical analysis
Results are reported as mean with standard deviation (SD). Normality testing was with the Shapiro-Wilk algorithm. Comparison of RT-with cold-stored PCs or RT with cryopreserved PCs, both standard and AS-PCT, was with two-way analysis of variance with Tukey's multiple-comparisons correction. Data are given as means with SD. Results from statistical analysis are depicted on top of the panels and are shown as *p < 0.05, **p < 0.01, ***p < 0.005, and ****p < 0.001. All statistical analyses were performed with statistical software (Prism, Version 6, GraphPad Software Inc.).
RESULTS
Mean PLT volume, PLT recovery, and glycocalicin release
Cryopreservation but also cold storage caused significant increases in mean PLT volume (MPV) compared to RT storage and this was irrespective of AS-PCT (Tables 1 and 2 ). PLT concentrations in AS-PCT-treated products were slightly lower than standard. Storage did not cause changes in PLT concentration (Table 1) . PLT recoveries after cryopreservation were not different between AS-PCT and standard PLTs (Table 2) . AS-PCT caused a 50% increase in GPIbα ectodomain shedding (i.e., glycocalicin release) compared to standard on D2 (Table 1) . Cold storage slightly attenuated GPIbα shedding caused by AS-PCT compared to RT storage. Cryopreservation is a significant instigator of GPIbα shedding irrespective of AS-PCT (Table 2) .
Cold storage PLT aggregation and integrin α IIb β 3 activation PAC-1 binding to PLTs was significantly lower for AS-PCT PLTs stored at 4 C (53% AE 9%) compared to RT (69% AE 13%, p = 0.0124). The decrease was smaller for standard PLTs stored at 4 C (77% AE 6%) compared to RT (85% AE 4%, p = 0.3429; Fig. 1A ). Comparable results were found for PLT aggregation with collagen. Aggregation amplitude was significantly lower for AS-PCT PLTs stored at 4 C (44% AE 11%) compared to RT storage (58% AE 21%, p = 0.0247). The decrease was smaller for standard PLTs stored at 4 C (57% AE 14%) compared to RT (62% AE 16%, p = 0.7399; Fig. 1B ). No visible aggregates were detected in any PC over the course of the study. Hemostasis in microfluidic flow chambers at elevated wall shear stress Platelet adhesion rate under flow was similar for AS-PCT and standard PLTs after storage irrespective of its temperature although it was significantly decreased before storage in AS-PCT compared to standard PLTs (p = 0.0196; Fig. 2A ). Coagulation under shear flow measured by the rate (Fig. 2B ) and the onset of coagulation (Fig. 2C ) decreased slightly but not 
Hemostatic function in static conditions by integrated thrombin generation
Peak thrombin concentration with standard PLTs was 98 AE 30 nmol/L before storage and increased to 102 AE 13 and 160 AE 3 nmol/L after RT and cold storage, respectively. However, in the presence of cold-stored AS-PCT PLTs the peak thrombin concentration doubled to 297 AE 47 nmol/L, which was significantly higher than for RT-stored AS-PCT PLTs (83 AE 25 nmol/L; p < 0.0001; Fig. 3A ). In line with increased peak thrombin, a shorter lag time (Fig. 3B ) and increased ETP (Fig. 3C) were found for cold-stored AS-PCT PLTs compared to RT-stored AS-PCT PLTs. To demonstrate that the assay was dependent on PLTs, other PLT concentrations were used yielding the same results (Fig. S1 , available as supporting information in the online version of this paper). Representative thrombograms of the condition with 50 × 10 9 PLTs/L are depicted in Fig. S2A , available as supporting information in the online version of this paper.
PS expression and MP release
Molecular regulators of PLT procoagulation are aminophospholipid expression and MP release. Fig. 4 shows that cold storage caused a significant increase in annexin V binding for both AS-PCT (33% AE 4%) and standard (16% AE 6%) PLTs compared to before storage (3% AE 1%). Yet, annexin V binding of cold-stored AS-PCT PLTs was double that of standard PLTs (p < 0.0001). Conversely, MP formation was more pronounced in standard (19% AE 6%) than in AS-PCT PLTs (10% AE 2%, p < 0.0001) after cold storage.
Cryopreservation

PLT aggregation and integrin α IIb β 3 activation
Binding of PAC-1 in response to PLT agonists decreased from 73% AE 6% before to 15% AE 5% after cryopreservation of AS-PCT PLTs while it decreased from 92% AE 2% to 26% AE 10% for standard PLTs (Fig. 5A) . The difference between AS-PCT and standard PLTs was significant before and after cryopreservation (p = 0.0015 and p = 0.0208, respectively). PLT aggregation was markedly reduced after cryopreservation and required a combination of strong agonists. There were no significant differences between AS-PCT and standard PLTs (Fig. 5B ).
Hemostatic function in static conditions by integrated thrombin generation
Thrombin generation in static conditions was significantly increased in the presence of cryopreserved PLTs. Output variables are peak thrombin concentrations (Figs. 6A, S3A , and S3B, available as supporting information in the online version of this paper), lag time (Figs. 6B, S3C, and S3D), and ETP (Figs. 6C, S3E , and S3F). AS-PCT treatment was not significantly different from standard except for a slight increase in peak thrombin (455 AE 37 nmol/L) compared to standard PLTs (419 AE 37 nmol/L) after cryopreservation (Fig. 6A ).
Representative thrombograms of the condition with 50 × 10 9
PLTs/L are depicted in Fig. S2B .
DISCUSSION
An increasing number of blood banking institutions worldwide are introducing pathogen inactivation for PCs. The Belgian Red Cross Flanders provides blood products to six million inhabitants, including PCs corresponding to 25,000 PLT transfusions annually. AS-PCT was introduced in our blood service in 2015. After AS-PCT implementation the Belgian federal regulator mandated shortening PC shelf life from 7 to 5 days after concerns on efficacy of AS-PCT-treated PLTs to stop bleeding. 21 This was a national decision and may not apply to other countries. The short shelf life is challenging for stock management in routine blood banking and more so in remote areas or isolated communities or during military operations. 29 Increasing PC shelf life therefore is an ongoing field of investigation and possible alternatives are cold storage and cryopreservation. Several studies have demonstrated that AS-PCT affects PLT function in vitro. Changes in gene transcription, 30 metabolism, 31 PLT thrombus formation under hydrodynamic flow, 22 and signal transduction 24 have all been reported.
These studies were performed using PLTs stored at RT. Cold storage reduces the proliferation rate of pathogens adding to product safety. However, the combined effect of AS-PCT and low-temperature storage has not been investigated until recently. 32 It is nonetheless relevant because both manipulations together may intensify or compensate each other's singular effect. 33 In addition, pathogen inactivation for PCs is mandatory in a number of European countries including Belgium, France, and Switzerland. Implementation of alternative storage methods in these countries would always have to take pathogen inactivation into account. Our study shows that cold storage affects PLT reactivity when combined with AS-PCT as demonstrated by decreased integrin α IIb β 3 activation in response to TRAP6 and decreased aggregation in response to collagen. This was different when investigating coagulation in the presence of PLTs, which decreased significantly after RT storage of AS-PCT PLTs but not after cold storage. This was observed in hydrodynamic as well as static conditions. These data suggest that cold storage either slows down storage lesion in AS-PCT PLTs or actively promotes the biochemistry of procoagulation. The former is unlikely because direct PLT activation assays were showed significantly decreased PLT function. These are archetypical in vitro hallmarks of storage lesion. Therefore, a direct change in PLT biochemistry linked to procoagulation is more likely given that twice the number of cold-stored AS-PCT PLTs express PS compared to cold-stored standard PLTs. Basic PLT biology studies have shown the importance of cell-based coagulation. This has shifted the concept of coagulation from a mere cascade of proteolytic reactions toward a cell surface-based protein complexation process. 34 For instance, in the absence of PLTs or PLT membranes, coagulation rates decrease by three orders of magnitude. 35 Essential to this catalytic function of PLTs are aminophospholipids like PS that support the assembly of the tenase and prothrombinase complexes on the lipid bilayer. Although the molecular basis is not entirely clear yet, conformation-dependent lipid-protein interactions are involved. 36 Consequently, the increased expression of PS on cold-stored AS-PCT PLTs is a possible explanation for the procoagulant character. In addition to PS expression, MP formation is another well-known mechanism of procoagulation. Sinauridze and colleagues 37 demonstrated that a surface area of PLT-derived MP is 50-to 100-fold more procoagulant than the same surface area on activated PLTs. In our study, however, MP formation cannot explain the procoagulant character of coldstored AS-PCT PLTs because significantly less MP are formed in AS-PCT PLTs than in standard PLTs. Several observational studies on the use of RT stored AS-PCT PLTs suggest that these are safe to use. [38] [39] [40] Whether cold-stored AS-PCT PLTs are safe to use in the clinic needs further study in vivo. We can only speculate on the safety of other procoagulant PLTs like those in cryopreserved PCs. 14, 17 Cryopreserved standard PLTs have been used in the Dutch military and a retrospective analysis suggested these are safe. 18 More recently, transfusion of cryopreserved standard PLTs in 24 bleeding thrombocytopenic patients in a prospective trial returned no serious adverse events. 19 In terms of clinical efficacy of cold-stored AS-PCT PLTs, two major questions need to be addressed. One concerns PLT clearance and the other concerns the actual potential to prevent or stop bleeding. Cold storage significantly decreases PLT life span after transfusion 2 and AS-PCT also leads to lower 24-hour corrected count increments (CCIs), 41 which explains the increased number of PLT transfusions per patient 42, 43 and which could partly explain the increased refractoriness. 42 It is not clear what the combined effect of cold storage and AS-PCT on CCIs would be. Several preclinical studies in mice have intensively examined PLT clearance mechanism but the mechanism is still incompletely understood. 8, 9, 44, 45 In mice PS exposure in cold-stored PLTs is a determinant of accelerated clearance. 46, 47 This may explain the accelerated PLT clearance found in all clinical trials with cold-stored PLTs. 2, 48 Our data show that the combination of AS-PCT and cold storage increases PS expression so requiring additional in vivo work to study this hypothesis. Another possible regulator of PLT clearance is the GPIbα receptor. Its clustering, 49 deglycosylation, 9, 50 or ectodomain shedding 46 all have been linked to PLT clearance in mice. Our data show that AS-PCT increases GPIbα shedding in all conditions, although it is 17% less when stored at 4 C compared to RT. This difference may contribute to longer circulation times of cold-stored AS-PCT compared to RT-stored AS-PCT PLTs but needs additional work in vivo. Even though PLT CCI is often used as a primary endpoint in trials, it determines PLT circulation kinetics and is therefore a surrogate for transfusion success. PLT transfusions are intended to prevent or stop bleeding. In (acute) trauma, for instance, PLT circulation time may be less important than hemostatic activity, but also in other indications like autologous stem cell transplantation, therapeutic transfusion may be favored over prophylactic 51 transfusion, although this may not apply in other indications. 52 Cryopreserved PLTs have been suggested to serve exactly that goal as a procoagulant agent with short circulation times. If such PLTs prove to be efficient to stop bleeding, the combination of AS-PCT and cold storage could constitute a product with very low risk of pathogen transmission in a subset of patients in acute need of treatment.
In summary, this study shows that cold storage of AS-PCT PLTs affects PLTs in activation and aggregation studies but promotes coagulation in static and flow conditions in vitro. Investigation of PLT circulation times and clinical efficacy are essential before considering implementation of these PLTs into routine blood banking.
